VK 2735
Alternative Names: VK-2735Latest Information Update: 30 Oct 2025
At a glance
- Originator Viking Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity
- Phase I Non-alcoholic steatohepatitis
- Preclinical Diabetes mellitus
Most Recent Events
- 21 Oct 2025 Viking Therapeutics initiates enrolment in a phase I maintenance study for Obesity (In volunteers) (PO, SC)
- 19 Aug 2025 Updated efficacy and adverse event data from the phase II VENTURE trial in Obesity released by Viking therapeutics
- 15 Aug 2025 Viking Therapeutics completes the phase II VVENTURE-Oral trial in Obesity in USA (PO) (NCT06828055)
